Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies - Test2 - elhamkhani - TriplyDB

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

http://www.wikidata.org/entity/Q24561905

about

Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10 CCR5 monoclonal antibodies for HIV-1 therapy Antibody vs. HIV in a clash of evolutionary titans bNAber: database of broadly neutralizing HIV antibodies Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors Catalytic antibodies to HIV: physiological role and potential clinical utility Antibody responses to envelope glycoproteins in HIV-1 infection HIV-1 neutralizing antibodies: understanding nature's pathways HIV broadly neutralizing antibody targets Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates Antibodies against viruses: passive and active immunization Structure of Antibody F425-B4e8 in Complex with a V3 Peptide Reveals a New Binding Mode for HIV-1 Neutralization A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120 Structure determination of an anti-HIV-1 Fab 447-52D–peptide complex from an epitaxially twinned data set A Conformational Switch in Human Immunodeficiency Virus gp41 Revealed by the Structures of Overlapping Epitopes Recognized by Neutralizing Antibodies Crystallographic Definition of the Epitope Promiscuity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5: Vaccine Design Implications Crystal structure of a 3B3 variantâ A broadly neutralizing HIV-1 scFv antibody Interactions between Lipids and Human Anti-HIV Antibody 4E10 Can Be Reduced without Ablating Neutralizing Activity Structural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based Immunogens Crystal Structure of the Neutralizing Llama VHH D7 and Its Mode of HIV-1 gp120 Interaction Conserved structural elements in the V3 crown of HIV-1 gp120 Elicitation of structure-specific antibodies by epitope scaffolds A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield Human Anti-V3 HIV-1 Monoclonal Antibodies Encoded by the VH5-51/VL Lambda Genes Define a Conserved Antigenic Structure Autoreactivity and Exceptional CDR Plasticity (but Not Unusual Polyspecificity) Hinder Elicitation of the Anti-HIV Antibody 4E10 Structure and Immunogenicity of a Peptide Vaccine, Including the Complete HIV-1 gp41 2F5 Epitope Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design The good and evil of complement activation in HIV-1 infection Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India Cross-Neutralizing Antibodies in HIV-1 Individuals Infected by Subtypes B, F1, C or the B/Bbr Variant in Relation to the Genetics and Biochemical Characteristics of the env Gene Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies A directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoprotein Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope Broad neutralization coverage of HIV by multiple highly potent antibodies

P2860

Q21089590-013AEC6D-9C81-45DB-AE10-37CBF7193531 Q22242739-1266D51B-A976-4B61-AF00-DD1D7AF44409 Q24536059-400581EC-B99A-4AC2-A333-9FC9567C2965 Q24567758-8BBBF986-37D4-4EC1-A5C4-386AFE08D202 Q24635002-3C826BA5-310F-4855-BCAF-0D9DAAED889F Q24655129-0BBC2311-DB19-4E19-B5C6-6F51CD40DB62 Q24655912-91519E46-D5E9-406A-86FE-B1B079369A1E Q26991572-6E8EB884-8761-41FA-B75B-D0A435C1B351 Q27000480-BDC29EED-876D-40D7-8361-E2BBA769B8B4 Q27026662-AD43C3C6-5F13-40C0-B670-E992EE60903B Q27320687-FC021809-ED66-4CB8-9E39-B3B14BC3C657 Q27485578-EF75E133-205B-4AAC-9EDA-E303789363C8 Q27489000-0361E151-FFB0-4DF6-9C16-D254E8541056 Q27489392-9FB40063-5A4B-47AA-8642-DB1A574B2690 Q27649247-46A47004-0EFF-42E5-9650-B4FE59C9F92A Q27649541-8442B627-9A58-4F75-B7F6-B09B2E988A3B Q27650903-C392DE65-FADB-4A3F-9981-4E8E3487498E Q27655865-23ACD34C-E78D-4BC6-9572-536E15973C10 Q27657377-12CD7D1E-176A-4422-8C67-91918CF2AC45 Q27657585-0EE76CB4-B06C-4A88-A5A9-2EDBDCECD5A2 Q27658138-1F4B63B0-C092-44B5-9F37-E23F66923AE2 Q27658173-1AB8D619-B42A-4110-BC5C-6B810196919E Q27661588-900F54B7-87AD-495E-9CD6-F2EA4C47E8D7 Q27663325-D0A098E5-8C99-41AC-A497-4A26A2CFB4B2 Q27664711-33355EFB-23FD-47FC-B6A2-6CE64EA0039C Q27675032-5DC7DC34-C7C1-49F6-82BE-C40BED8A9D84 Q27676155-18921A27-AA5A-4F2F-99D0-BB07457236CA Q27680125-5935BC7E-09C6-4725-84B7-A00E061E48DA Q27681352-3F3C2210-4B13-4C5E-8FD0-C055DED19667 Q27684578-5588A89F-5AB2-4333-9ECD-A8EBEA80BEEC Q28075274-530B4AB4-71BE-4B86-85FA-DB5513781EFD Q28275986-949DEED6-6A46-4898-BB81-B394268100FA Q28469023-FAD95EC5-8557-45F3-9FB4-AD36D744F3E6 Q28483205-A0C15124-8100-42E5-B576-36666CEB0F61 Q28554907-023AFFBF-8419-4AE6-91EC-D074590A1FAB Q28602877-1B0F83DB-9522-4999-A9E5-FC43DCC7F817 Q28743092-87563ADB-A948-4CBD-A537-43628C1EF7DE Q28752503-D7A613B5-9240-4B73-A569-87DA543A2813 Q29307502-AC993980-FA86-4DE2-9E95-79D4C5F9C5A9 Q29615361-C41724DB-496E-403B-9072-D9B9301C7D7C

P2860

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

http://www.wikidata.org/entity/Q24561905

description

2004 nî lūn-bûn

@nan

2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

name

Comprehensive cross-clade neut ...... s type 1 monoclonal antibodies

@ast

Comprehensive cross-clade neut ...... s type 1 monoclonal antibodies

@en

Comprehensive cross-clade neut ...... s type 1 monoclonal antibodies

@nl

type

label

Comprehensive cross-clade neut ...... s type 1 monoclonal antibodies

@ast

Comprehensive cross-clade neut ...... s type 1 monoclonal antibodies

@en

Comprehensive cross-clade neut ...... s type 1 monoclonal antibodies

@nl

prefLabel

Comprehensive cross-clade neut ...... s type 1 monoclonal antibodies

@ast

Comprehensive cross-clade neut ...... s type 1 monoclonal antibodies

@en

Comprehensive cross-clade neut ...... s type 1 monoclonal antibodies

@nl

P1433

Q24561905-5F52D3B0-D2DC-4B0E-A8C3-A6A0F6D1594E

P1476

Q24561905-46377EC8-DC31-4EB8-9BAE-7B776267B96D

P2093

Q24561905-3B319CC3-4899-4627-92D0-1C9AD45050A3

Q24561905-3B9CCBD0-4D38-458C-A80A-C511D7B9ACC5

Q24561905-91716ADC-71E6-4FCE-9100-067EFF471A62

Q24561905-9ED1453A-A6D4-45DD-867E-9A2F89839CB6

Q24561905-9F58AEC0-AA8D-42FE-AAC8-E9F262F6B60D

Q24561905-C2625CD5-E03F-4CC1-A953-72CFB7277846

Q24561905-C968A748-1025-4845-A21A-19ACD9EB8823

Q24561905-F020BC74-329B-4717-8DC5-FE3C8F6A4B91

Q24561905-F5AC9131-E70E-42C9-AFBE-747C0FAAF5E5

P2860

Q24561905-00523E55-AAC7-4483-852B-E60FB7685064

Q24561905-00C91CCA-C691-40D1-B6E5-91F559421F39

Q24561905-04A9A902-DF16-45AD-961B-4B2B7EFBAC85

Q24561905-0507179A-8B41-4C59-8D79-8BAFB8C4087E

Q24561905-089B6C83-F3BB-4C1A-89CD-BCC38FE54DEF

Q24561905-0A3228A3-2474-497F-8B51-267173AD49FD

Q24561905-0D58BA1E-3A39-46C1-8DE4-C8D016D0862A

Q24561905-10D8F8EF-123F-475B-A1CA-9B7F665C7F41

Q24561905-112353E4-8738-415A-B975-1471C5ABE604

Q24561905-19E76873-B188-41A0-83FF-4F2A5852DA40

P304

Q24561905-F96AB870-B3CE-411B-A449-E84B85224E9C

P31

Q24561905-314C7615-5B61-44A5-B74C-50BD7FE4014C

P3181

Q24561905-57C6E9DF-B289-4FA9-82F9-9609CFFE803D

P356

Q24561905-3A3543E9-40A0-4CA7-BB55-45AD6B5F68A2

P407

Q24561905-0E55B88E-6A2F-4CD2-90F8-6C4D29EEA55F

P433

Q24561905-165F2EE2-466E-4576-9176-EFF52D330C6A

P478

Q24561905-8567ECF0-DFB5-4B67-B2D4-82F0020BA001

P50

Q24561905-34E4B4EB-8E2E-4220-B84B-F455CDCF1CC5

Q24561905-772E3634-63DF-4B05-A780-4EB73E72B868

Q24561905-B79E1E66-0D1E-4008-AC0F-11CCDEFAD319

P577

Q24561905-1D07D534-2E10-48BE-8E74-606B1EB02808

P698

Q24561905-46BC1E88-6DCB-4053-A8ED-3935E351F753

P921

Q24561905-8DBF70D9-5340-45BD-9EC8-E8F2FD02AD31

Q24561905-B9D92A64-2229-4C9C-84D4-49CEA29B8091

P932

Q24561905-6A98AF86-ACEC-42D4-AF77-96B295B91A78

P3181

P356

JVI.78.23.13232-13252.2004

P1433

Journal of Virology

P1476

Comprehensive cross-clade neut ...... s type 1 monoclonal antibodies

@en

P2093

Colombe Chappey

http://www.w3.org/2001/XMLSchema#string

Dennis R Burton

http://www.w3.org/2001/XMLSchema#string

Gabriela Stiegler

http://www.w3.org/2001/XMLSchema#string

Hermann Katinger

http://www.w3.org/2001/XMLSchema#string

James M Binley

http://www.w3.org/2001/XMLSchema#string

Meng Wang

http://www.w3.org/2001/XMLSchema#string

Michael B Zwick

http://www.w3.org/2001/XMLSchema#string

Susan Zolla-Pazner

http://www.w3.org/2001/XMLSchema#string

Terri Wrin

http://www.w3.org/2001/XMLSchema#string

P2860

Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.

A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals

Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1

Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

P304

13232-52

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1379316

http://www.w3.org/2001/XMLSchema#string

P356

10.1128/JVI.78.23.13232-13252.2004

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

78

http://www.w3.org/2001/XMLSchema#string

P50

Christos J Petropoulos

P577

2004-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15542675

http://www.w3.org/2001/XMLSchema#string

P921

P932

524984

http://www.w3.org/2001/XMLSchema#string